Coagulation factor VIIa Recombinant Human
- Generic Name
- Coagulation factor VIIa Recombinant Human
- Brand Names
- Niastase RT, Novoseven, Sevenfact, NovoSeven
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 102786-61-8
- Unique Ingredient Identifier
- AC71R787OV
- Background
Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
- Indication
For treatment of hemorrhagic complications in hemophilia A and B.
- Associated Conditions
- Bleeding, Bleeding caused by Hemophilia A, Bleeding caused by Hemophilia B, Severe Bleeding
- Associated Therapies
- -
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 102
- Registration Number
- NCT00703911
- Locations
- 🇻🇪
Novo Nordisk Investigational Site, Caracas, Venezuela
Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT00697320
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
- Conditions
- Interventions
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT00486278
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
rhuFVIIa in Post-partum Hemorrhage
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Target Recruit Count
- 84
- Registration Number
- NCT00370877
- Locations
- 🇫🇷
University Hospital of Montpellier, Montpellier, France
🇫🇷University Hospital, Nice, Nice, France
🇫🇷Hôpital Antoine Béclère -APHP, Clamart, France
Factor VIIa in Acute Intracerebral Haemorrhage
- Conditions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 90
- Registration Number
- NCT00266006
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 554
- Registration Number
- NCT00184548
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States
Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)
- Conditions
- Interventions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 30
- Registration Number
- NCT00128050
- Locations
- 🇮🇹
Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
🇮🇹Azienda Ospedaliera "Maggiore della Carità", Novara, Italy
🇮🇹II Dpt Anesthesiology&Critical Care Medicine - IRCCS Policlinico S. Matteo, Pavia, Italy
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
- Conditions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 829
- Registration Number
- NCT00127283
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Trial of NovoSeven® in Haemophilia - Joint Bleeds
- Conditions
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT00108797
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States
Use of Activated Recombinant FVII in Spinal Surgery
- Conditions
- First Posted Date
- 2005-01-20
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT00102037
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.